The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Patrys’ (PAB) subsidiary Nucleus Theraputics receives a more than $600,000 research and development (R&D) tax incentive refund
  • Melbourne-based Patrys develops antibodies to treat a range of cancers
  • The incentive from the Federal Government encourages companies to engage in R&D that will benefit Australia
  • Patrys CEO and Managing Director Dr James Campbell says the funds enable PAB to get the first of its deoxymab developments into the clinic
  • Company shares are up 3.2 per cent to 3.2 cents each at 1:58 pm AEST

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the 2019/20 financial year.

Based in Melbourne, Patrys is focussed on developing its deoxymab platform of cell-penetrating antibodies as therapies for a range of cancers.

Administered by the Australian Federal Government, the incentive encourages companies to engage in R&D that will benefit Australia, by providing a refundable tax offset of up to 43.5 per cent for eligible activities.

“This rebate, on top of the $7.3 million capital raising that Patrys completed in December 2020, provides sufficient funds for Patrys to get the first of its deoxymabs into the clinic,” Patrys CEO and Managing Director Dr James Campbell said.

So far, PAB has developed two humanised forms of deoxymab, PAT-DX1 and PAT-DX3, which it says have improved activity compared with the original deoxymab antibody.

The company is undertaking final preclinical studies and pharmacetucal-grade, scale-up manufacturing of PAT-DX1.

On the market this afternoon, Patrys shares were trading 3.2 per cent higher at 3.2 cents at 1:58 pm AEST.

PAB by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system